Myriad: the oral arguments


On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.

Myriad, Supreme Court, oral arguments, BRCA1, human gene, DNA, patents

More on this story

US Supreme Court strikes Myriad blow